{"id":"amitriptylinoxide","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Proto-oncogene tyrosine-protein kinase receptor Ret","category":"target"},{"label":"RET","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_3","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:32:50.710608","allNames":"amitriptyline oxide","offLabel":[],"synonyms":["amitriptylinoxide","amitriptyline N-oxide","amitriptyline oxide"],"timeline":[],"brandName":"Amitriptyline Oxide","ecosystem":[],"mechanism":{"target":"Proto-oncogene tyrosine-protein kinase receptor Ret","targets":[{"gene":"RET","source":"DrugCentral","target":"Proto-oncogene tyrosine-protein kinase receptor Ret","protein":"Proto-oncogene tyrosine-protein kinase receptor Ret"}],"modality":"Small Molecule","explanation":"Think of it like a key fitting into a lock. Amitriptylinoxide is the key that blocks the receptor, which is like a switch that controls cell growth. By blocking this switch, amitriptylinoxide may help slow down or stop the growth of cancer cells.","oneSentence":"Amitriptylinoxide works by binding to and inhibiting the proto-oncogene tyrosine-protein kinase receptor Ret.","technicalDetail":"Amitriptylinoxide is a small molecule inhibitor that binds to the extracellular domain of the proto-oncogene tyrosine-protein kinase receptor Ret, preventing the receptor's dimerization and subsequent activation of downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/181","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMITRIPTYLINOXIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMITRIPTYLINOXIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:43:57.517017","biosimilars":[],"competitors":[{"drugName":"alectinib","drugSlug":"alectinib","fdaApproval":"2015-12-11","patentExpiry":"May 29, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"axitinib","drugSlug":"axitinib","fdaApproval":"2012-01-27","patentExpiry":"Jun 14, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"baricitinib","drugSlug":"baricitinib","fdaApproval":"2018-05-31","patentExpiry":"Nov 30, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bosutinib","drugSlug":"bosutinib","fdaApproval":"2012-09-04","patentExpiry":"Nov 23, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cabozantinib","drugSlug":"cabozantinib","fdaApproval":"2012-11-29","patentExpiry":"Oct 8, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"ceritinib","drugSlug":"ceritinib","fdaApproval":"2014-04-29","patentExpiry":"Nov 20, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"crizotinib","drugSlug":"crizotinib","fdaApproval":"2011-08-26","patentExpiry":"Oct 8, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cyclobenzaprine","drugSlug":"cyclobenzaprine","fdaApproval":"1977-08-26","patentExpiry":"Mar 14, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dasatinib","drugSlug":"dasatinib","fdaApproval":"2006-06-28","patentExpiry":"Sep 28, 2026","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"amitriptylinoxide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(28)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alectinib","brandName":"alectinib","genericName":"alectinib","approvalYear":"2015","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"axitinib","brandName":"axitinib","genericName":"axitinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"baricitinib","brandName":"baricitinib","genericName":"baricitinib","approvalYear":"2018","relationship":"same-target"},{"drugId":"bosutinib","brandName":"bosutinib","genericName":"bosutinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"cabozantinib","brandName":"cabozantinib","genericName":"cabozantinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"ceritinib","brandName":"ceritinib","genericName":"ceritinib","approvalYear":"2014","relationship":"same-target"},{"drugId":"crizotinib","brandName":"crizotinib","genericName":"crizotinib","approvalYear":"2011","relationship":"same-target"},{"drugId":"cyclobenzaprine","brandName":"cyclobenzaprine","genericName":"cyclobenzaprine","approvalYear":"1977","relationship":"same-target"},{"drugId":"dasatinib","brandName":"dasatinib","genericName":"dasatinib","approvalYear":"2006","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT02237937","phase":"PHASE4","title":"Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene","status":"UNKNOWN","sponsor":"HolsboerMaschmeyer NeuroChemie GmbH","startDate":"2011-09","conditions":["Major Depression"],"enrollment":80,"completionDate":"2014-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"006696","UNII":"TYR2U59WMA","CHEBI":"CHEBI:135224","INN_ID":"3926","RXNORM":"236734","UMLSCUI":"C0051694","ChEMBL_ID":"CHEMBL627","KEGG_DRUG":"D07449","DRUGBANK_ID":"DB13114","PUBCHEM_CID":"20313","MESH_SUPPLEMENTAL_RECORD_UI":"C006566"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":28,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 28","pmid":"41638625","title":"Drug repositioning for human MKN45 gastric cancer mouse model using deep learning AI and experimental validation.","journal":"European journal of pharmacology"},{"date":"2024 Apr 29","pmid":"38679721","title":"Acupuncture versus tricyclic antidepressants in the prophylactic treatment of tension-type headaches: an indirect treatment comparison meta-analysis.","journal":"The journal of headache and pain"},{"date":"2012 Oct","pmid":"22859791","title":"Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).","journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"date":"2004 Oct","pmid":"15554244","title":"The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man.","journal":"Drug metabolism reviews"},{"date":"1999 Oct","pmid":"10554658","title":"Effects of amitriptyline, amitriptylinoxide, doxepine and clozapine on N-methyl-D-aspartate-evoked release of [3H]-acetylcholine in rat caudatoputamen.","journal":"Arzneimittel-Forschung"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amitriptylinoxide is a small molecule modality targeting the proto-oncogene tyrosine-protein kinase receptor Ret. However, due to the lack of available information, its exact mechanism of action, approved indications, and commercial status are unknown. Further research is needed to determine its potential as a therapeutic agent. As a result, it is not possible to provide a comprehensive summary of its key safety considerations. More data is required to understand its pharmacokinetic properties and potential side effects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}